Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Clin Pharmacol Ther. 2020 Oct 2;109(3):705–715. doi: 10.1002/cpt.2039

Figure 1. Study Population by CYP2C19 Metabolizer Phenotype and Antiplatelet Therapy.

Figure 1.

Flow diagram describing the number of study participants by CYP2C19 Metabolizer Phenotype (ultrarapid or rapid metabolizers [UM or RM], normal metabolizers [NM], intermediate or poor metabolizers [IM or PM] by the prescribed P2Y12 inhibitor therapy during follow-up (clopidogrel or alternative therapy).